Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,860 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. Fox E, et al. Clin Cancer Res. 2006 Aug 15;12(16):4882-7. doi: 10.1158/1078-0432.CCR-06-0534. Clin Cancer Res. 2006. PMID: 16914576 Clinical Trial.
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.
Meany HJ, Sackett DL, Maris JM, Ward Y, Krivoshik A, Cohn SL, Steinberg SM, Balis FM, Fox E. Meany HJ, et al. Among authors: fox e. Pediatr Blood Cancer. 2010 Jan;54(1):47-54. doi: 10.1002/pbc.22267. Pediatr Blood Cancer. 2010. PMID: 19731320 Free PMC article. Clinical Trial.
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM. Widemann BC, et al. Among authors: fox e. Clin Cancer Res. 2012 Nov 1;18(21):6011-22. doi: 10.1158/1078-0432.CCR-11-3284. Epub 2012 Sep 7. Clin Cancer Res. 2012. PMID: 22962440 Free PMC article. Clinical Trial.
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
Mossé YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH, Blaney SM. Mossé YP, et al. Among authors: fox e. Clin Cancer Res. 2012 Nov 1;18(21):6058-64. doi: 10.1158/1078-0432.CCR-11-3251. Epub 2012 Sep 17. Clin Cancer Res. 2012. PMID: 22988055 Free PMC article. Clinical Trial.
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S. Bagatell R, et al. Among authors: fox e. Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874. Epub 2013 Nov 19. Pediatr Blood Cancer. 2014. PMID: 24249672 Free PMC article. Clinical Trial.
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Fox E, et al. Pediatr Blood Cancer. 2014 Jun;61(6):990-6. doi: 10.1002/pbc.24900. Epub 2013 Dec 18. Pediatr Blood Cancer. 2014. PMID: 24347462 Free PMC article. Clinical Trial.
1,860 results